MedTrace Logo

Comparison of Kaltenborn Mobilization and Mobilization With Movement (MWM) in Wrist Hypomobility After Colle's Fracture

NCT07060430 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-07-11

No results posted yet for this study

Summary

This study is a randomised control trial and the purpose of this study is to determine comparision of Kaltenborn Mobilization and Mobilization with Movement (MWM) in wrist Hpomobility after Colle's fracture.

Conditions

  • Colles Fracture
  • Hypomobility

Interventions

PROCEDURE

Kaltenborn Mobilization

All participants received a standardized treatment regimen first. This began with the application of a hot pack or infrared therapy for 10 to 15 minutes at the start of each session. then this group will receive Kaltenborn mobilizations with each mobilization technique performed for 10 repetitions, and each repetition maintained for 2 to 3 seconds. Mobilizations included palmar (volar) glide, dorsal glide, radial glide, and ulnar glide. In addition to wrist mobilizations, anterior and posterior glides were applied to the distal radioulnar joint.

PROCEDURE

Mulligan Mobilization with Movement

All participants received a standardized treatment regimen first. This began with the application of a hot pack or infrared therapy for 10 to 15 minutes at the start of each session. then this group will receive Mulligan's Mobilization with Movement (MWM) technique, which involved 10 repetitions of each mobilization, with each repetition held for 2 to 3 seconds. First, a lateral glide or rotational movement of the carpal bones on the radius was applied, accompanied by the patient actively performing the intended wrist movement, such as flexion, extension, or deviation. Second, an ulnar-directed mobilization of the radius was provided simultaneously with active patient movement.

Sponsors & Collaborators

  • Foundation University Islamabad

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-15
Primary Completion
2025-06-30
Completion
2025-06-30

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07060430 on ClinicalTrials.gov